Explore IgA nephropathy, a rare autoimmune kidney disease where the IgA protein builds up in the kidneys. Normally, IgA helps protect against infections, but in this condition, it changes shape and sticks to other proteins, causing inflammation and damage. This can lead to kidney scarring and impaired function. Early detection and treatment are crucial for managing the disease and protecting kidney function.
In this heartfelt video, four different patients share their journies with IgA nephropathy, kidney failure, and the eventual need for a transplant. Initially unaware of their conditions, they…
Dana V. Rizk, MD, professor of medicine, University of Alabama at Birmingham; and Gerald Appel, MD, professor of medicine and co-director of the Center for Glomerular Disease, Columbia…
Jonathan Barratt, MD, University of Leicester, UK, discusses the need for improved continuity of care for patients with IgA nephropathy. Professor Barratt notes that the rarity of the…
This video discusses the risk factors for IgA nephropathy, a disease with no single known cause. While anyone can develop it, certain groups are at higher risk, including…
This video discusses the management of IgA nephropathy, a common and incurable kidney disease. Treatment aims to control the disease and delay kidney damage progression. Lifestyle changes, such…
Clarissa Tio, MD, a nephrologist at the University of Mississippi, moderates a discussion between Ariana Barton, a patient living with IgA nephropathy and a patient advocate, Joshua Samuels,…
Dana Rizk, MD, professor of medicine at the University of Alabama at Birmingham, discusses the approval of Fabhalta (iptacopan) for adults with IgA nephropathy. Iptacopan, a Factor B…
Anand Reddy, MRCP (UK), FACP, FASN, Permian Regional Medical Center, Andrews, Texas; and Richard Lafayette, MD, FASN, professor of medicine and director of the Stanford Glomerular Disease Center,…
Josh Galdi, PharmD, BCPS and Hannah N. Lambert, PharmD discuss the current understanding of IgA nephropathy with Anor Shaw, MD. They explore the nature of this common glomerular…
Obi Umeh, MD, MSc, VP, Franchise Global Program Leader at Takeda, discusses interim results from a study investigating mezagitamab for the treatment of patients with IgA nephropathy. This…
